威尔明顿，德尔州，2月1日，221年，/ - 杜邦（纽约证券交易所代码：DD）今天宣布完成IFF和营养和生物科学的合并。与IFF交易结束时，杜邦收到约73亿美元的特殊现金支付，其中约50亿美元将用于通过退休的未偿还债务来加强资产负债表。
合并完成后，杜邦将以更敏锐的战略重点向前推进，并正在对其报告结构进行某些有针对性的调整。自2021年2月1日起，杜邦将有三个业务报告部门:电子与工业、移动与材料和水与保护。每一家公司都将拥有市场领先的企业，拥有深厚的专业知识、差异化的产品和技术，以及赢得客户、超越同行、为股东带来价值的必要能力。
杜邦执行董事长兼首席执行官埃德·布林表示:“我们进入2021年将处于强势地位。今天的杜邦是一家领先的多行业公司，通过选择性和有针对性的并购来推动有机增长和扩展我们的业务。我们拥有正确的业务、产品和结构，以满足客户的需求，并充分利用我们所选择的终端市场的显著增长趋势。我们的新结构结合了具有共同财务特征的业务，使整个公司的视野更加清晰，资源配置更加有效。每一家公司都有有意义的增长前景，其管理团队懂得如何最佳地执行其优先事项，并为股东带来利益。”
杜邦还宣布，已完成对非核心业务的战略评估。与此相关，该公司宣布已与一家国际私募股权财团达成最终协议，以5.1亿美元出售杜邦清洁技术业务。该交易预计将在2021年第二季度完成，取决于惯例的成交条件和监管部门的批准。此外，杜邦还认为，它在推动Tedlar®、Microcircuit Materials和DuPont Teijin Films合资企业的价值方面处于最佳位置，并将这些业务重新调整为Mobility & Materials。随着宣布的与生物材料和清洁技术相关的协议，从2021年2月1日起，杜邦将解散其非核心报告部门。
Breen继续，“我致敬通过长期过渡和持续的大流行挑战所展示的员工。他们强调我们的核心价值观，以及我们的客户和彼此的支持，帮助建立了我们站立的强大基础在今天，随着全球经济迁移恢复，致力于成长。“
可以找到更新的报告部分的概述，包括业务线和投资组合调整这里。该公司将在2021年2月9日与投资者进行的2020年第四季度收益网络直播中提供更多相关细节。
对杜邦公司
杜邦公司(NYSE: DD)是全球创新领导者，以科技为基础的材料、配料和解决方案帮助改变工业和日常生活。我们的员工运用不同的科学和专业知识，帮助客户在电子、交通、建筑、水、健康和保健、食品和工人安全等关键市场推进他们的最佳理念，并提供必要的创新。有关该公司、其业务和解决方案的更多信息，请访问www.lufeng-fst.com。投资者可访问网站投资者关系部分的信息，网址为investors.dupont.com。
Dupont™，Dupont椭圆标志，以及用™表示的所有商标和服务标记，SM或者®除非另有说明，否则由Dupont de Nemours，Inc的附属公司拥有。
关于营养和生物科学
营养和生物科学应用专家科学，以推进食品，饮料，膳食补充剂和制药行业的市场驱动，健康和可持续的解决方案。我们还在一系列市场使用尖端生物技术来推进基于生物的解决方案，以满足人口不断增长的需求，同时保护我们的环境为后代。我们是创新的求解器，帮助客户将挑战变成高价值商机。
关于前瞻性陈述的注意事项
该沟通在联邦证券法的含义中包含“前瞻性陈述”，包括“证券法”第27A条，以及1934年“修订”的“证券交流法”第21E条（“交流法”）。在这方面，前瞻性陈述往往地满足预期的未来业务和财务绩效和财务状况，通常包含“期待”等词语“预期”，“打算”，“计划，”“求，”“求，”“请参阅，”“遗嘱，”，“目标，”类似的表情，以及这些词的变化或否定。他们的自然地址的前瞻性陈述，对不同程度，不确定的事项，如关于交易的陈述，交易的好处和协同作用，联合公司和产品的未来机会，拟议的组织和运营的好处合并公司的型号和关于杜邦，IFF和N＆B的未来行动，财务或经营业绩，资本配置，股息政策，债务率，预期的业务水平，未来盈利，计划活动，预期增长，市场机会，策略，金融或经营业绩，资本配置，资本分配，竞争以及未来时期的其他期望和目标。有几个因素可能导致实际计划和结果与前瞻性陈述中表达或暗示的那些不同。这些因素包括但不限于（1）缔约方能够满足关于交易的会计和税收处理的预期，（2）相关税和其他法律的变化，（3）可能是不可预见的负债，未来资本支出，收入，费用，利润，协同效应，经济绩效，负债，财务状况，亏损，未来的发展前景，经营和管理策略，可能会影响交易的价值，（4）风险和相关Corteva的分销成本2019年6月1日（“Corteva Distribution”）和Dow Inc.的分销2019年4月1日（“Dow分布”和Corteva分配“以前的分布”），包括某些遗留负债的赔偿 of E. I. du Pont de Nemours and Company ("Historical EID"), a subsidiary of Corteva, in connection with the Corteva Distribution and potential liability arising from fraudulent conveyance and similar laws in connection with the Previous Distributions, (5) risks and costs related to the performance under and impact of the cost sharing arrangement by and between DuPont, Corteva, Inc. and The Chemours Company related to future eligible PFAS liabilities, (6) failure to effectively manage acquisitions, divestitures, alliances, joint ventures and other portfolio changes, including meeting conditions under the Letter Agreement entered in connection with the Corteva Distribution, related to the transfer of certain levels of assets and businesses, (7) uncertainty as to the long-term value of DuPont common stock, (8) potential inability or reduced access to the capital markets or increased cost of borrowings, including as a result of a credit rating downgrade, (9) inherent uncertainties involved in the estimates and judgments used in the preparation of financial statements and the providing of estimates of financial measures, in accordance with the accounting principles generally accepted in the United States of America and related standards, or on an adjusted basis, (10) the integration of IFF and its Frutarom business and/or N&B being more difficult, time consuming or costly than expected, (11) the failure to achieve expected or targeted future financial and operating performance and results, (12) the possibility that IFF may be unable to achieve expected benefits, synergies and operating efficiencies in connection with the transaction within the expected time frames or at all or to successfully integrate Frutarom and N&B, (13) customer loss and business disruption being greater than expected following the transaction, (14) legislative, regulatory and economic developments; (15) an increase or decrease in the anticipated transaction taxes (including due to any changes to tax legislation and its impact on tax rates (and the timing of the effectiveness of any such changes)), (16) potential litigation relating to the transaction that could be instituted against DuPont, IFF or their respective directors, (17) risks associated with third party contracts containing consent and/or other provisions that may be triggered by the transaction, (18) negative effects of the consummation of the transaction on the market price of DuPont's and/or IFF's common stock, (19) risks relating to the value of the IFF shares to be issued in the transaction and uncertainty as to the long-term value of IFF's common stock, (20) the impact of the failure to comply with U.S. or foreign anti-corruption and anti-bribery laws and regulations, (21) the ability of N&B or IFF to retain and hire key personnel, (26) the risk that N&B and IFF will incur significant indebtedness in connection with the transaction, and the degree to which IFF will be leveraged following completion of the transaction may materially and adversely affect its business, financial condition and results of operations, (23) that N&B may not achieve certain targeted cost and productivity improvements, which could adversely impact its results of operations and financial condition, and (24) other risks to DuPont's, N&B's and IFF's business, operations and results of operations including from: failure to develop and market new products and optimally manage product life cycles; ability, cost and impact on business operations, including the supply chain, of responding to changes in market acceptance, rules, regulations and policies and failure to respond to such changes; outcome of significant litigation, environmental matters and other commitments and contingencies; failure to appropriately manage process safety and product stewardship issues; global economic and capital market conditions, including the continued availability of capital and financing, as well as inflation, interest and currency exchange rates; changes in political conditions, including tariffs, trade disputes and retaliatory actions; impairment of goodwill or intangible assets; the availability of and fluctuations in the cost of energy and raw materials; business or supply disruption, including in connection with the Previous Distributions; security threats, such as acts of sabotage, terrorism or war, natural disasters and weather events and patterns, disasters, public health issues, epidemics and pandemics, including COVID-19, or the fear of such events, and the inherent unpredictability, duration and severity of such events, which could result in a significant operational event for DuPont, N&B or IFF, adversely impact demand or production; ability to discover, develop and protect new technologies and to protect and enforce DuPont's, N&B's or IFF's intellectual property rights;, as well as management's response to any of the aforementioned factors. These risks, as well as other risks associated with the merger, are more fully discussed in the registration statement and proxy statement filed by IFF and the registration statement filed by N&B. While the list of factors presented here is, and the list of factors presented in registration statements filed by each of IFF and N&B in connection with the transaction, are considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Further lists and descriptions of risks and uncertainties can be found in IFF's annual report on Form 10-K for the year ended December 31, 2019, DuPont's annual report on Form 10-K for the year ended December 31, 2019, and each of IFF's and DuPont's respective subsequent reports on Form 10-Q, Form 10-K and Form 8-K, the contents of which are not incorporated by reference into, nor do they form part of, this announcement. Any other risks associated with the transaction are more fully discussed in the registration statements filed with the SEC. While the list of factors presented here is, and the list of factors presented in the registration statements, as amended, filed by each of IFF or N&B are representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on IFF's, DuPont's or N&B's consolidated financial condition, results of operations, credit rating or liquidity. None of IFF, DuPont nor N&B assumes any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.
有关交易的其他信息以及在哪里找到它
这种沟通并非旨在，不构成出售或征集出售要约或征求要约的要约，以便购买任何证券或征求批准的投票，也不应销售证券销售在任何此类管辖权的证券法下的登记或资格之前，任何司法管辖区都将是非法的，在任何此类管辖权的证券法下是非法的。除了招股说明书外，不得进行证券的提议，该招股说明书符合1933年“证券法”第10条规定的招股说明书（“证券法”）。与交易有关，N＆B已向2020年12月31日的举行招股说明书提交了关于载人的招股说明书的注册声明，IFF向12月31日发送了招股说明书的S-4的注册声明，2020（共同，“注册陈述”）和杜邦向SEC提交了一个计划。敦促投资者和安全持有人向这些文件的注册报表，杜邦的进度和任何修正案或补充，以及在可用时提交的任何其他相关文件或者将其提交，因为它们包含关于N＆B的重要信息，iff和dupont和交易。登记陈述，杜邦的计划和与交易有关的其他文件（当它们可用时）也可以免费获得SEC网站的www.sec.gov。这些文件和每个公司的其他文件与SEC(可用时)也可以免费获得,杜邦和n和b,在书面请求我国LLC在美洲的1290大道,9号楼,纽约,纽约10104,或通过电话888-660-8331,或者,敌我识别,请向纽约10019 West 57 Street 521号的International flavor & Fragrances Inc.投资者关系部提出书面请求或致电(212)708-7164。
此外，对于任何有关交换要约的问题，一般您可以联系信息代理Georgeson LLC，电话888-660-8331。
查看原始内容以下载多媒体：http://www.prnewswire.com/news-releases/dupont-positioned-as-premier-multi-industrial-company-equipped-for-growth-and-value-creation-following-completion-of-iff-and-nutrition--biosciences-merger-301218858.html
源杜邦